PI 2620

Drug Profile

PI 2620

Alternative Names: PI-2620

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AC Immune
  • Developer AC Immune; Piramal Imaging
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 15 Aug 2017 Pharmacokinetics data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 30 Jun 2016 Phase I clinical trials in Alzheimer's disease (Diagnosis) (Parenteral) before June 2016
  • 12 May 2014 Preclinical trials in Alzheimer's disease (Diagnosis) in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top